Therapy Evaluation Program News Today

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

Diversity in patient populations, including age, race, ethnicity, and underrepresented regions, have increased in early-phase National Cancer Institute-sponsored trials.

Compared to the year 2000, a greater proportion of NCI-sponsored early-phase clinical trial participants in 2022 were older, from minority racial/ethnic groups, and lived in historically underrepresented regions of the U.S., according to a study presented at the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held September 29-October 2, 2023.

- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high...

Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace

For results from clinical trials to be more generalizable, there needs to be some loosening of exclusion criteria, say researchers who report that some headway has been made.

The proportion of AYAs enrolled in clinical trials increased after the launch of the National Clinical Trials Network in 2014.

The proportion of adolescents and young adults (AYAs; aged 15 to 39 years) enrolled in clinical trials increased after launch of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) in 2014.